We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+40.84%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$14.2M
(+8.8%)
Cap. Flow
-$31.4M
Cap. Flow % of AUM
Cap. Flow %
-17.91%
Top 10 Holdings %
Top 10 Hldgs %
92.73%
Holding
17
New
1
Increased
2
Reduced
1
Closed
1
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIEN
Sientra
SIEN
|
+$4.46M |
| 2 |
AVEO
AVEO Pharmaceuticals
AVEO
|
+$948K |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$827K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$37M |
| 2 |
Dermira
DERM
|
+$559K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q2 2018 Portfolio in Review
As of Q2 2018, Abingworth held 17 positions worth $175M, up 8.8% from $161M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Abingworth withdrew a net $31.4M in Q2 2018, closing 1 position and reducing 1 holding. Its most notable exit was Dermira, an estimated $559K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Abingworth opened a new position in AVEO Pharmaceuticals worth $900K.
- Abingworth's largest Q2 2018 buy was AVEO Pharmaceuticals: 40,000 shares worth $900K.
- Abingworth added most to Sientra in Q2 2018, an estimated $4.46M increase.
- Abingworth's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $37M.
- Abingworth fully exited Dermira in Q2 2018, selling an estimated $559K.
- Abingworth's ten largest holdings make up 93% of its $175M portfolio in Q2 2018.
- Abingworth opened 1 new position and closed 1 in Q2 2018.
- Abingworth's portfolio value rose 8.8% quarter-over-quarter to $175M.
Based on Abingworth's 13F filing for Q2 2018, filed 14 Aug 2018.